Clinical covariates influencing clinical outcomes in primary membranous nephropathy
Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification of risk groups and could result...
Saved in:
Published in | BMC nephrology Vol. 24; no. 1; p. 235 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
10.08.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification of risk groups and could result in more individualized therapy recommendations.
In this single-center retrospective observational study, we analyze the effect of patient-specific and therapy-associated covariates on proteinuria, hypoalbuminemia, and estimated glomerular filtration rate (eGFR) in 74 patients diagnosed with antibody positive PMN and nephrotic-range proteinuria (urine-protein-creatinine-ratio [UPCR] ≥ 3.5 g/g), treated at the University of Freiburg Medical Center between January 2000 - November 2022. The primary endpoint was defined as time to proteinuria / serum-albumin response (UPCR ≤ 0.5 g/g or serum-albumin ≥ 3.5 g/dl), the secondary endpoint as time to permanent eGFR decline (≥ 40% relative to baseline).
The primary endpoint was reached after 167 days. The secondary endpoint was reached after 2413 days. Multivariate time-to-event analyses showed significantly faster proteinuria / serum-albumin response for higher serum-albumin levels (HR 2.7 [95% CI: 1.5 - 4.8]) and cyclophosphamide treatment (HR 3.6 [95% CI: 1.3 - 10.3]). eGFR decline was significantly faster in subjects with old age at baseline (HR 1.04 [95% CI: 1 - 1.1]).
High serum-albumin levels, and treatment with cyclophosphamide are associated with faster proteinuria reduction and/or serum-albumin normalization. Old age constitutes a risk factor for eGFR decline in subjects with PMN. |
---|---|
AbstractList | BACKGROUNDPrimary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification of risk groups and could result in more individualized therapy recommendations. METHODSIn this single-center retrospective observational study, we analyze the effect of patient-specific and therapy-associated covariates on proteinuria, hypoalbuminemia, and estimated glomerular filtration rate (eGFR) in 74 patients diagnosed with antibody positive PMN and nephrotic-range proteinuria (urine-protein-creatinine-ratio [UPCR] ≥ 3.5 g/g), treated at the University of Freiburg Medical Center between January 2000 - November 2022. The primary endpoint was defined as time to proteinuria / serum-albumin response (UPCR ≤ 0.5 g/g or serum-albumin ≥ 3.5 g/dl), the secondary endpoint as time to permanent eGFR decline (≥ 40% relative to baseline). RESULTSThe primary endpoint was reached after 167 days. The secondary endpoint was reached after 2413 days. Multivariate time-to-event analyses showed significantly faster proteinuria / serum-albumin response for higher serum-albumin levels (HR 2.7 [95% CI: 1.5 - 4.8]) and cyclophosphamide treatment (HR 3.6 [95% CI: 1.3 - 10.3]). eGFR decline was significantly faster in subjects with old age at baseline (HR 1.04 [95% CI: 1 - 1.1]). CONCLUSIONHigh serum-albumin levels, and treatment with cyclophosphamide are associated with faster proteinuria reduction and/or serum-albumin normalization. Old age constitutes a risk factor for eGFR decline in subjects with PMN. Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification of risk groups and could result in more individualized therapy recommendations. In this single-center retrospective observational study, we analyze the effect of patient-specific and therapy-associated covariates on proteinuria, hypoalbuminemia, and estimated glomerular filtration rate (eGFR) in 74 patients diagnosed with antibody positive PMN and nephrotic-range proteinuria (urine-protein-creatinine-ratio [UPCR] ≥ 3.5 g/g), treated at the University of Freiburg Medical Center between January 2000 - November 2022. The primary endpoint was defined as time to proteinuria / serum-albumin response (UPCR ≤ 0.5 g/g or serum-albumin ≥ 3.5 g/dl), the secondary endpoint as time to permanent eGFR decline (≥ 40% relative to baseline). The primary endpoint was reached after 167 days. The secondary endpoint was reached after 2413 days. Multivariate time-to-event analyses showed significantly faster proteinuria / serum-albumin response for higher serum-albumin levels (HR 2.7 [95% CI: 1.5 - 4.8]) and cyclophosphamide treatment (HR 3.6 [95% CI: 1.3 - 10.3]). eGFR decline was significantly faster in subjects with old age at baseline (HR 1.04 [95% CI: 1 - 1.1]). High serum-albumin levels, and treatment with cyclophosphamide are associated with faster proteinuria reduction and/or serum-albumin normalization. Old age constitutes a risk factor for eGFR decline in subjects with PMN. Background Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification of risk groups and could result in more individualized therapy recommendations. Methods In this single-center retrospective observational study, we analyze the effect of patient-specific and therapy-associated covariates on proteinuria, hypoalbuminemia, and estimated glomerular filtration rate (eGFR) in 74 patients diagnosed with antibody positive PMN and nephrotic-range proteinuria (urine-protein-creatinine-ratio [UPCR] [greater than or equal to] 3.5 g/g), treated at the University of Freiburg Medical Center between January 2000 - November 2022. The primary endpoint was defined as time to proteinuria / serum-albumin response (UPCR [less than or equal to] 0.5 g/g or serum-albumin [greater than or equal to] 3.5 g/dl), the secondary endpoint as time to permanent eGFR decline ([greater than or equal to] 40% relative to baseline). Results The primary endpoint was reached after 167 days. The secondary endpoint was reached after 2413 days. Multivariate time-to-event analyses showed significantly faster proteinuria / serum-albumin response for higher serum-albumin levels (HR 2.7 [95% CI: 1.5 - 4.8]) and cyclophosphamide treatment (HR 3.6 [95% CI: 1.3 - 10.3]). eGFR decline was significantly faster in subjects with old age at baseline (HR 1.04 [95% CI: 1 - 1.1]). Conclusion High serum-albumin levels, and treatment with cyclophosphamide are associated with faster proteinuria reduction and/or serum-albumin normalization. Old age constitutes a risk factor for eGFR decline in subjects with PMN. Keywords: Primary membranous nephropathy, PLA2-R, THSD7A, Chronic kidney disease, Immunosuppression, Nephrotic syndrome, Rituximab Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification of risk groups and could result in more individualized therapy recommendations. In this single-center retrospective observational study, we analyze the effect of patient-specific and therapy-associated covariates on proteinuria, hypoalbuminemia, and estimated glomerular filtration rate (eGFR) in 74 patients diagnosed with antibody positive PMN and nephrotic-range proteinuria (urine-protein-creatinine-ratio [UPCR] [greater than or equal to] 3.5 g/g), treated at the University of Freiburg Medical Center between January 2000 - November 2022. The primary endpoint was defined as time to proteinuria / serum-albumin response (UPCR [less than or equal to] 0.5 g/g or serum-albumin [greater than or equal to] 3.5 g/dl), the secondary endpoint as time to permanent eGFR decline ([greater than or equal to] 40% relative to baseline). The primary endpoint was reached after 167 days. The secondary endpoint was reached after 2413 days. Multivariate time-to-event analyses showed significantly faster proteinuria / serum-albumin response for higher serum-albumin levels (HR 2.7 [95% CI: 1.5 - 4.8]) and cyclophosphamide treatment (HR 3.6 [95% CI: 1.3 - 10.3]). eGFR decline was significantly faster in subjects with old age at baseline (HR 1.04 [95% CI: 1 - 1.1]). High serum-albumin levels, and treatment with cyclophosphamide are associated with faster proteinuria reduction and/or serum-albumin normalization. Old age constitutes a risk factor for eGFR decline in subjects with PMN. Abstract Background Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification of risk groups and could result in more individualized therapy recommendations. Methods In this single-center retrospective observational study, we analyze the effect of patient-specific and therapy-associated covariates on proteinuria, hypoalbuminemia, and estimated glomerular filtration rate (eGFR) in 74 patients diagnosed with antibody positive PMN and nephrotic-range proteinuria (urine-protein-creatinine-ratio [UPCR] ≥ 3.5 g/g), treated at the University of Freiburg Medical Center between January 2000 – November 2022. The primary endpoint was defined as time to proteinuria / serum-albumin response (UPCR ≤ 0.5 g/g or serum-albumin ≥ 3.5 g/dl), the secondary endpoint as time to permanent eGFR decline (≥ 40% relative to baseline). Results The primary endpoint was reached after 167 days. The secondary endpoint was reached after 2413 days. Multivariate time-to-event analyses showed significantly faster proteinuria / serum-albumin response for higher serum-albumin levels (HR 2.7 [95% CI: 1.5 – 4.8]) and cyclophosphamide treatment (HR 3.6 [95% CI: 1.3 – 10.3]). eGFR decline was significantly faster in subjects with old age at baseline (HR 1.04 [95% CI: 1 – 1.1]). Conclusion High serum-albumin levels, and treatment with cyclophosphamide are associated with faster proteinuria reduction and/or serum-albumin normalization. Old age constitutes a risk factor for eGFR decline in subjects with PMN. Abstract Background Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification of risk groups and could result in more individualized therapy recommendations. Methods In this single-center retrospective observational study, we analyze the effect of patient-specific and therapy-associated covariates on proteinuria, hypoalbuminemia, and estimated glomerular filtration rate (eGFR) in 74 patients diagnosed with antibody positive PMN and nephrotic-range proteinuria (urine-protein-creatinine-ratio [UPCR] ≥ 3.5 g/g), treated at the University of Freiburg Medical Center between January 2000 – November 2022. The primary endpoint was defined as time to proteinuria / serum-albumin response (UPCR ≤ 0.5 g/g or serum-albumin ≥ 3.5 g/dl), the secondary endpoint as time to permanent eGFR decline (≥ 40% relative to baseline). Results The primary endpoint was reached after 167 days. The secondary endpoint was reached after 2413 days. Multivariate time-to-event analyses showed significantly faster proteinuria / serum-albumin response for higher serum-albumin levels (HR 2.7 [95% CI: 1.5 – 4.8]) and cyclophosphamide treatment (HR 3.6 [95% CI: 1.3 – 10.3]). eGFR decline was significantly faster in subjects with old age at baseline (HR 1.04 [95% CI: 1 – 1.1]). Conclusion High serum-albumin levels, and treatment with cyclophosphamide are associated with faster proteinuria reduction and/or serum-albumin normalization. Old age constitutes a risk factor for eGFR decline in subjects with PMN. |
ArticleNumber | 235 |
Audience | Academic |
Author | Staudacher, Dawid L Rottmann, Felix A Arnold, Frederic Westermann, Lukas Wobser, Rika Welte, Thomas Hug, Martin J |
Author_xml | – sequence: 1 givenname: Lukas surname: Westermann fullname: Westermann, Lukas organization: Department of Medicine IV, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 2 givenname: Felix A surname: Rottmann fullname: Rottmann, Felix A organization: Department of Medicine IV, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 3 givenname: Martin J surname: Hug fullname: Hug, Martin J organization: Pharmacy, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 4 givenname: Dawid L surname: Staudacher fullname: Staudacher, Dawid L organization: Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 5 givenname: Rika surname: Wobser fullname: Wobser, Rika organization: Department of Medicine IV, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany – sequence: 6 givenname: Frederic surname: Arnold fullname: Arnold, Frederic email: frederic.arnold@uniklinik-freiburg.de, frederic.arnold@uniklinik-freiburg.de organization: Institute for Microbiology and Hygiene, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. frederic.arnold@uniklinik-freiburg.de – sequence: 7 givenname: Thomas surname: Welte fullname: Welte, Thomas email: thomas.welte@uniklinik-freiburg.de, thomas.welte@uniklinik-freiburg.de organization: Institute for Microbiology and Hygiene, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. thomas.welte@uniklinik-freiburg.de |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37563703$$D View this record in MEDLINE/PubMed |
BookMark | eNptkk1v1DAQhi1URD_gD3BAkbhwSfF3nBOqVtBWqsQBOFvOxN71KrEXO6naf4_3o6WLkA-2Zp557Rm_5-gkxGARek_wJSFKfs6EKkVrTFmNWTnWD6_QGeENqSmT7cmL8yk6z3mNMWkUx2_QKWuEZA1mZ-jHYvDBgxkqiPcmeTPZXPnghtkG8GFZwVM-zhPEcZetNsmPJj1Wox27ZEKccxXsZpXixkyrx7fotTNDtu8O-wX69e3rz8VNfff9-nZxdVeDkHyqqevb3nWu6xh3wmDRC2zBWUU7YqTqKWdgOTOGSwyiVZxwaqzrATplWdOzC3S71-2jWevDm3Q0Xu8CMS21SZOHwWoQIAXBLbQOeNtKg23LCHHAlHQS86L1Za-1mbvR9mDDlMxwJHqcCX6ll_FeE8wJE5gVhU8HhRR_zzZPevQZ7DCYYMuANFWFwkxIWtCP_6DrOKdQZrWlaMEokX-ppSkdlD-J5WLYiuqrRmLW4oaJQl3-hyqrt6OHYhjnS_yogO4LIMWck3XPTRKst77Se1_p4iu985V-KEUfXo7nueTJSOwPw8zLig |
CitedBy_id | crossref_primary_10_1186_s12882_023_03309_9 crossref_primary_10_1007_s10157_024_02470_1 crossref_primary_10_22141_2307_1257_12_4_2023_431 |
Cites_doi | 10.3389/fimmu.2021.593288 10.1016/S0140-6736(02)11042-7 10.1371/journal.pone.0214614 10.18637/jss.v036.i02 10.7326/0003-4819-139-4-200308190-00006 10.1016/S0140-6736(96)11445-8 10.1016/S0272-6386(00)70190-9 10.1172/JCI72270 10.1016/S0140-6736(71)92572-4 10.1056/NEJM199307083290203 10.1016/S0140-6736(12)61566-9 10.1097/MD.0000000000001560 10.1038/s41572-021-00303-z 10.1016/j.kint.2019.09.014 10.1186/s12882-018-0828-2 10.1038/ki.1995.453 10.1681/ASN.2020071091 10.1056/NEJMoa0810457 10.1016/j.kint.2020.05.030 10.1056/NEJMoa1114248 10.1016/S0033-0620(95)80011-5 10.1016/j.kint.2020.10.014 10.1016/j.kint.2016.09.048 10.1046/j.1523-1755.2001.0590041484.x 10.21105/joss.03139 10.1056/NEJMoa1409354 10.1007/s10157-011-0477-2 10.1038/ki.1986.209 10.1053/ajkd.1998.v31.pm9428445 |
ContentType | Journal Article |
Copyright | 2023. BioMed Central Ltd., part of Springer Nature. COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. BioMed Central Ltd., part of Springer Nature 2023 |
Copyright_xml | – notice: 2023. BioMed Central Ltd., part of Springer Nature. – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: BioMed Central Ltd., part of Springer Nature 2023 |
DBID | NPM AAYXX CITATION 3V. 7QP 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12882-023-03288-x |
DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: ProQuest_Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2369 |
EndPage | 235 |
ExternalDocumentID | oai_doaj_org_article_c5c65109c9fc4996a0e9311fc386f604 A760390735 10_1186_s12882_023_03288_x 37563703 |
Genre | Journal Article |
GeographicLocations | Germany |
GeographicLocations_xml | – name: Germany |
GrantInformation_xml | – fundername: Deutsche Forschungsgemeinschaft grantid: 431984000 – fundername: ; – fundername: ; grantid: 431984000; 431984000; 431984000 |
GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK IAO IHR INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX CITATION ABVAZ AFGXO AFNRJ 7QP 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c564t-2fd9dfbfbb34f5a05d50ecfe82b1a68d243ce43aa460c5984142aefdccb8e37d3 |
IEDL.DBID | RPM |
ISSN | 1471-2369 |
IngestDate | Tue Oct 22 15:14:12 EDT 2024 Tue Sep 17 21:31:39 EDT 2024 Fri Aug 16 12:05:37 EDT 2024 Thu Oct 10 16:19:22 EDT 2024 Fri Feb 23 00:20:09 EST 2024 Fri Feb 02 04:41:32 EST 2024 Thu Sep 12 17:48:57 EDT 2024 Wed Oct 16 00:38:23 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Immunosuppression PLA2-R Primary membranous nephropathy Rituximab Chronic kidney disease Nephrotic syndrome THSD7A |
Language | English |
License | 2023. BioMed Central Ltd., part of Springer Nature. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c564t-2fd9dfbfbb34f5a05d50ecfe82b1a68d243ce43aa460c5984142aefdccb8e37d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413503/ |
PMID | 37563703 |
PQID | 2852030216 |
PQPubID | 44769 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c5c65109c9fc4996a0e9311fc386f604 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10413503 proquest_miscellaneous_2850303562 proquest_journals_2852030216 gale_infotracmisc_A760390735 gale_infotracacademiconefile_A760390735 crossref_primary_10_1186_s12882_023_03288_x pubmed_primary_37563703 |
PublicationCentury | 2000 |
PublicationDate | 2023-08-10 |
PublicationDateYYYYMMDD | 2023-08-10 |
PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-10 day: 10 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC nephrology |
PublicationTitleAlternate | BMC Nephrol |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | B Combes (3288_CR9) 1971; 2 MP Fay (3288_CR20) 2010; 36 R Xu (3288_CR27) 2015; 94 K Disease (3288_CR16) 2021; 100 Team RC (3288_CR18) 2013 Group TG (3288_CR25) 1997; 349 DC Cattran (3288_CR31) 2001; 59 JG Heaf (3288_CR12) 2018; 19 LH Beck Jr (3288_CR4) 2009; 361 S Sethi (3288_CR7) 2020; 98 DBSM Lüdecke (3288_CR21) 2021; 16 YT Chen (3288_CR23) 2019; 14 F Scolari (3288_CR34) 2021; 32 A Howman (3288_CR32) 2013; 381 TB Clarkson (3288_CR15) 1995; 38 C Ponticelli (3288_CR14) 1995; 48 TH Jafar (3288_CR26) 2003; 139 P Ruggenenti (3288_CR29) 2000; 35 T Therneau (3288_CR19) 2013 CE Alpers (3288_CR11) 1986; 30 RT Gansevoort (3288_CR28) 1992; 7 LJ Reichert (3288_CR24) 1998; 31 AM Davison (3288_CR1) 1984; 22 A Numata (3288_CR10) 2011; 15 LA Inker (3288_CR17) 2012; 367 DC Cattran (3288_CR3) 2017; 91 G Remuzzi (3288_CR30) 2002; 360 S Sethi (3288_CR6) 2020; 97 LH Beck Jr (3288_CR2) 2014; 124 A Schieppati (3288_CR13) 1993; 329 P Ronco (3288_CR22) 2021; 7 G Fernandez-Juarez (3288_CR33) 2021; 99 NM Tomas (3288_CR5) 2014; 371 V Tesar (3288_CR8) 2021; 12 |
References_xml | – volume: 12 start-page: 593288 year: 2021 ident: 3288_CR8 publication-title: Front Immunol doi: 10.3389/fimmu.2021.593288 contributor: fullname: V Tesar – volume: 360 start-page: 923 issue: 9337 year: 2002 ident: 3288_CR30 publication-title: Lancet doi: 10.1016/S0140-6736(02)11042-7 contributor: fullname: G Remuzzi – volume: 14 start-page: e0214614 issue: 4 year: 2019 ident: 3288_CR23 publication-title: PLoS One doi: 10.1371/journal.pone.0214614 contributor: fullname: YT Chen – volume: 36 start-page: i02 issue: 2 year: 2010 ident: 3288_CR20 publication-title: J Stat Softw doi: 10.18637/jss.v036.i02 contributor: fullname: MP Fay – volume: 139 start-page: 244 issue: 4 year: 2003 ident: 3288_CR26 publication-title: Ann Intern Med doi: 10.7326/0003-4819-139-4-200308190-00006 contributor: fullname: TH Jafar – volume: 349 start-page: 1857 issue: 9069 year: 1997 ident: 3288_CR25 publication-title: Lancet doi: 10.1016/S0140-6736(96)11445-8 contributor: fullname: Group TG – volume: 35 start-page: 381 issue: 3 year: 2000 ident: 3288_CR29 publication-title: Am J Kidney Dis doi: 10.1016/S0272-6386(00)70190-9 contributor: fullname: P Ruggenenti – volume: 124 start-page: 2307 issue: 6 year: 2014 ident: 3288_CR2 publication-title: J Clin Invest doi: 10.1172/JCI72270 contributor: fullname: LH Beck Jr – volume: 2 start-page: 234 issue: 7718 year: 1971 ident: 3288_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(71)92572-4 contributor: fullname: B Combes – volume: 329 start-page: 85 issue: 2 year: 1993 ident: 3288_CR13 publication-title: N Engl J Med doi: 10.1056/NEJM199307083290203 contributor: fullname: A Schieppati – volume: 381 start-page: 744 issue: 9868 year: 2013 ident: 3288_CR32 publication-title: Lancet doi: 10.1016/S0140-6736(12)61566-9 contributor: fullname: A Howman – volume: 100 start-page: S1 issue: 4S year: 2021 ident: 3288_CR16 publication-title: Kidney Int contributor: fullname: K Disease – volume: 94 start-page: e1560 issue: 39 year: 2015 ident: 3288_CR27 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000001560 contributor: fullname: R Xu – volume: 7 start-page: 69 issue: 1 year: 2021 ident: 3288_CR22 publication-title: Nat Rev Dis Primers doi: 10.1038/s41572-021-00303-z contributor: fullname: P Ronco – volume: 97 start-page: 163 issue: 1 year: 2020 ident: 3288_CR6 publication-title: Kidney Int doi: 10.1016/j.kint.2019.09.014 contributor: fullname: S Sethi – volume: 22 start-page: 61 issue: 2 year: 1984 ident: 3288_CR1 publication-title: Clin Nephrol contributor: fullname: AM Davison – volume: 19 start-page: 27 issue: 1 year: 2018 ident: 3288_CR12 publication-title: BMC Nephrol doi: 10.1186/s12882-018-0828-2 contributor: fullname: JG Heaf – volume: 48 start-page: 1600 issue: 5 year: 1995 ident: 3288_CR14 publication-title: Kidney Int doi: 10.1038/ki.1995.453 contributor: fullname: C Ponticelli – volume: 32 start-page: 972 issue: 4 year: 2021 ident: 3288_CR34 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2020071091 contributor: fullname: F Scolari – volume: 361 start-page: 11 issue: 1 year: 2009 ident: 3288_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa0810457 contributor: fullname: LH Beck Jr – volume: 98 start-page: 1253 issue: 5 year: 2020 ident: 3288_CR7 publication-title: Kidney Int doi: 10.1016/j.kint.2020.05.030 contributor: fullname: S Sethi – volume: 367 start-page: 20 issue: 1 year: 2012 ident: 3288_CR17 publication-title: N Engl J Med doi: 10.1056/NEJMoa1114248 contributor: fullname: LA Inker – volume: 7 start-page: 91 issue: Suppl 1 year: 1992 ident: 3288_CR28 publication-title: Nephrol Dial Transplant contributor: fullname: RT Gansevoort – volume: 38 start-page: 189 issue: 3 year: 1995 ident: 3288_CR15 publication-title: Prog Cardiovasc Dis doi: 10.1016/S0033-0620(95)80011-5 contributor: fullname: TB Clarkson – volume: 99 start-page: 986 issue: 4 year: 2021 ident: 3288_CR33 publication-title: Kidney Int doi: 10.1016/j.kint.2020.10.014 contributor: fullname: G Fernandez-Juarez – volume: 91 start-page: 566 issue: 3 year: 2017 ident: 3288_CR3 publication-title: Kidney Int doi: 10.1016/j.kint.2016.09.048 contributor: fullname: DC Cattran – volume-title: R survival package. R Core Team year: 2013 ident: 3288_CR19 contributor: fullname: T Therneau – volume: 59 start-page: 1484 issue: 4 year: 2001 ident: 3288_CR31 publication-title: Kidney Int doi: 10.1046/j.1523-1755.2001.0590041484.x contributor: fullname: DC Cattran – volume: 16 start-page: 3139 issue: 60 year: 2021 ident: 3288_CR21 publication-title: J Open Source Softw doi: 10.21105/joss.03139 contributor: fullname: DBSM Lüdecke – volume-title: R: A language and environment for statistical computing year: 2013 ident: 3288_CR18 contributor: fullname: Team RC – volume: 371 start-page: 2277 issue: 24 year: 2014 ident: 3288_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa1409354 contributor: fullname: NM Tomas – volume: 15 start-page: 769 issue: 5 year: 2011 ident: 3288_CR10 publication-title: Clin Exp Nephrol doi: 10.1007/s10157-011-0477-2 contributor: fullname: A Numata – volume: 30 start-page: 465 issue: 4 year: 1986 ident: 3288_CR11 publication-title: Kidney Int doi: 10.1038/ki.1986.209 contributor: fullname: CE Alpers – volume: 31 start-page: 1 issue: 1 year: 1998 ident: 3288_CR24 publication-title: Am J Kidney Dis doi: 10.1053/ajkd.1998.v31.pm9428445 contributor: fullname: LJ Reichert |
SSID | ssj0017840 |
Score | 2.3852308 |
Snippet | Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by... Abstract Background Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely... Background Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by... BackgroundPrimary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by... BACKGROUNDPrimary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by... Abstract Background Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 235 |
SubjectTerms | Albumin Analysis Antibodies Biopsy Care and treatment Chronic kidney disease Chronic kidney failure Clinical outcomes Creatinine Cyclophosphamide Development and progression Disease Dosage and administration Epidermal growth factor receptors Glomerular filtration rate Glomerulonephritis Immunosuppression Immunotherapy Membranous nephropathy Nephrology Nephropathy Nephrotic syndrome Patient outcomes Patients Physiology, Pathological PLA2-R Prevention Primary membranous nephropathy Proteins Proteinuria Risk factors Risk groups Steroids Testing THSD7A Trends Urine Variables Viral antibodies |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV29a90wED9KhtKlNP10kwYHCh2KiaWTZHlMS0IIpEsbyCYs-UQDjV9oXkr63_dky49nOnTp6pONfN-HdL8DeG-RSMdWVSQaqlQUnm2OdGV96uNUvhdNak6--GLOLtX5lb7aGvWV7oRN8MAT446CDob1pg1tDJydm66mFoWIAa2JJiOBCj0XU_n8oOG6ZW6Rsebojr0wZ5Icn6qEH2erh0UYGtH6__bJW0FpeWFyKwKdPoOnOXUsj6ct78IjGp7D44t8OP4CvmaMzx9lWP3iEjhlkeV1HkLCEaqcuyDL1f2aFW2klrcT3ER5QzdcOCfA1nKg2zQ8gXPD3y_h8vTk2-ezKs9MqII2al3J2Ld99NF7VFF3te51TSGSlV50xvZSYSCFXadMHXRrlVCyo9iH4C1h0-Mr2BlWA72BElFTlCRNQFQee4_sOWsVuCJp6uCbAj7OLHR5r24sKaxxE8MdM9yNDHcPBXxKXN6sTLDW4wMWtsvCdv8SdgEfkoxcMj4WROhyDwFvOMFYuWPeIHK5j7qA_cVKNpqwJM9Sdtlo75y0WrLPk8IUcLghpzfTRbSBWAJpDS9BzhoLeD0pxeaXsNEG2YMWYBfqsvjnJWW4_j5CenNRLJC__PZ_cGkPnshR1RNw7z7srH_e0ztOndb-YLSSP_FxFt8 priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFD_oBuKL-G11SgTBBylrcpI0fZJNNoawIepgb6FJEx249rp7J_O_96Q3va4Ivja5t8n5Pk3O7wC8MRiCio0sA69DKSN3pHNBlcalOk7pOl6n4uTjE310Kj-eqbP8wW2Zr1VONnE01N3g0zfyXWGUIIEUXL9f_CxT16h0uppbaNyGbcFlOqbd3j84-fR5c45QU_4ylcoYvbska0wRJfmpMuHImfJ65o5G1P5_bfMN5zS_OHnDEx3eh3s5hGR7a54_gFuhfwh3jvMh-SP4krE-fzA__KJUOEWT7Dw3IyFPxaZqSDZcrWjz4yhbrGEn2EW4oAQ6AbeyPixSEwWKEX8_htPDg68fjsrcO6H0SstVKWLXdNFF51BG1VaqU1XwMRjheKtNJyT6ILFtpa68aozkUrQhdt47E7Du8Als9UMfngFDVCGKILRHlA47h2RBK-kpM6kr7-oC3k0ktHmtdkwtjLZrglsiuB0Jbq8L2E9U3sxM8Nbjg-Hym83aYr3ymoxF45voKSXTbRUa5Dx6NDrSuwt4m3hkkxISI3ybawlowQnOyu7RApHSflQF7MxmkvL4-fDEZZuVd2n_iloBrzfD6ZfpQlofiANpDk1Bih4LeLoWis2WsFYayZIWYGbiMtvzfKQ__z5Ce1NyzJH--fn_1_UC7opRiBM07w5srS6vwksKjlbuVdaAP6DXEDU priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFD-MDcQX0flV3aSC4INU25wkTR_GmMMxhOuLXthbaNITHWy9292dbP-9J_24rjh87Unb5OR8kpzfAXhnkEiFSmZUlJTJUDjWOVKZcbGOU7qmKGNx8uybPp7LryfqZAPGdkcDA6_uTe1iP6n58uzjzeXtPiv8XqfwRn-6YhvLcSJ7nyyiw5mMY8otIVFGiZ_Jv6cKpekLJNkgZwJ1NRbR3PuNiaPq8Pz_tdp33Nb0SuUdH3X0GB4NwWV60EvDE9igdhsezIbj86fwfUABPUv94jcnyTHOTE-HNiXsw9KxTjJdXK9YFDtqetEDUqTndM6pdYR0TVu6iO0VOHq8fQbzoy8_Do-zoatC5pWWq0yEpmqCC86hDKrOVaNy8oGMcEWtTcOM8ySxrqXOvaqMLKSoKTTeO0NYNvgcNttFSy8hRVQUBAntEaXDxiHb1lx6zlnK3LsygQ8jC-0wV9slHUbbnuGWGW47htubBD5HLq9HRuDr7sFi-dMOemS98prNSOWr4DlZ03VOFRZF8Gh04H8n8D7ukY0Cwxvh66HKgCccga7sAU8QK7ZrKoGdyUhWKz8lj7tsR6m0wijBVlEUOoG3a3J8M15Va4l3II7hIchxZQIveqFYLwlLpZFtbAJmIi6TNU8p7emvDvSb0-YC-cuv_j_t1_BQdEIcQXt3YHO1vKZdDptW7k2nC38AGbET_g priority: 102 providerName: Scholars Portal |
Title | Clinical covariates influencing clinical outcomes in primary membranous nephropathy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37563703 https://www.proquest.com/docview/2852030216 https://search.proquest.com/docview/2850303562 https://pubmed.ncbi.nlm.nih.gov/PMC10413503 https://doaj.org/article/c5c65109c9fc4996a0e9311fc386f604 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDsZexr7nrQseDPYw3Ng-SZYf09JSAillXSFvwpKlLdA4oU1H99_vpMihZm97scGSsXzfP_vuBPBForXc1SyzRWUz5gpNOmd5JrWv42S6LSpfnDy7EOfXbDrn8z0QfS1MSNo3enHU3SyPusWvkFu5Xppxnyc2vpydEIQokOc43of9CrHH6PHfQUWYpS-PkWJ8RxaYokjyTZnvHSezh4ELCp36_7XHjxzSMFnykfc5ewHPY9iYTrbLewl7tnsFT2fxx_hruIr9PW9Ss_pN8NdHkOkibkBC3intKyDT1f2GhCyMputtq4l0aZcEmn2z1rSza79xAsWFf97A9dnpj5PzLO6XkBku2CYrXVu3TjutkTne5LzluTXOylIXjZBtydBYhk3DRG54LVnBysa61hgtLVYtvoWDbtXZ95AicutKWwqDyDS2Gslq5swQGqlyo6sEvvUkVHGtKsAJKdSW4IoIrgLB1UMCx57Ku5m-pXW4sLr9qSJjleFGkIGoTe0MwTDR5LbGonAGpXD07AS-eh4pr3jECNPE-gFasG9hpSa0QCSojzyBw8FMUhgzHO65rKLC3qlS8pLsXVmIBD7vhv2dPgmts8QBP4emIEWMCbzbCsXulbDiAsl6JiAH4jJ45-EISXdo591L84f_v_UjPCuDgPtWvYdwsLm9t58oWNroEWnIvBrBk8lkejWl8_HpxeX3Ufj0QMcZk6OgPX8B0HccUg |
link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkYAL4k2gQJCQOKCoscd2nBMqiGqBbi-00t6s2LGhEk2W7haVf8846yyNkLjGTmLP-0s8MwCvNXovQy0KzypfiMAs6ZyXhbYxj1PYllUxOXl-pGYn4vNCLtIHt1U6VjnaxMFQt72L38j3uJacBJIz9W75s4hdo-Lf1dRC4zrcEIgiynm12AIuVhF6GRNltNpbkS2meJK8VBGryOnicuKMhpr9_1rmK65pemzyih86uAt3UgCZ7284fg-u-e4-3JynX-QP4Guq9Pkjd_0vAsIxlsxPUysS8lP5mAuZ9xdr2vowmi83RSfyM39G8DmWbc07v4wtFChC_P0QTg4-Hn-YFalzQuGkEuuCh7Zugw3WogiyKWUrS--C19yyRumWC3ReYNMIVTpZa8EEb3xonbPaY9XiI9jp-s4_gRxR-sA9V44IbLG1SPazFI5wSVU6W2XwdiShSWs1A7DQymwIbojgZiC4uczgfaTydmYsbj1c6M-_maQrxkmnyFTUrg6OAJlqSl8jY8GhVoHencGbyCMTVZAY4ZqUSUALjsWszD4tEAn0o8xgdzKTVMdNh0cum6S6K_NX0DJ4tR2Od8bjaJ0nDsQ5NAUpdszg8UYotlvCSiokO5qBnojLZM_Tke70-1DYm6AxQ3ry0_-v6yXcmh3PD83hp6Mvz-A2HwQ6FundhZ31-YV_TmHS2r4YdOEP-ZERvA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkSouvB-BAkFC4oCySfyKcyyFVXlsVQkqVeJgxY4NK7rZVTeLCr-eceKsGrj1mpkoduYtz3wGeCWptdyVLLF5YRPmco02Z3kitZ_jZLrOCz-cPDsShyfs4yk_DV2V69BW2Rg9nzRni0kz_9H1Vq4WJh36xNLj2QGWEDnlGU1XtUuvww00WlIMlXo4QSiwchmGZKRI1-iHMZfECJV4BDmZXIwCUYfX_79XvhSWxi2Tl2LQ9DZ8G1bft578nGxaPTF__gF2vNr27sCtkJrG-z3PXbhmm3uwOwuH7_fhS8AQPYvN8heW2D5LjefhkhOMgPEwZRkvNy0qckeNVz2cRbywCyzMPSBs3NiVv5wBc8_fD-Bk-v7rwWES7mRIDBesTYiry9pppzVljlcZr3lmjbOS6LwSsiaMGstoVTGRGV5KljNSWVcbo6WlRU0fwk6zbOxjiCnl1hFLhKGUaVprip45YwYrniIzuojgzSAgFdaqupJFCtWLU6E4VSdOdRHBWy_DLaeHze4eLM-_q_B3leFGoBMqTekMlnqiymxJ89wZKoXDb0fw2muA8saNYjZVmFHABXuYLLWPC6QlekUewd6IE43SjMmDDqngFNaKSE7Qp5JcRPByS_Zv-ka3xqIEPA-yUMxKI3jUq9x2S7TggqKHjkCOlHG05zEFVayDDB9U6snVX30Bu8fvpurzh6NPT-Em6SzJIwPvwU57vrHPMDdr9fPOCP8CK-07Dg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+covariates+influencing+clinical+outcomes+in+primary+membranous+nephropathy&rft.jtitle=BMC+nephrology&rft.au=Westermann%2C+Lukas&rft.au=Rottmann%2C+Felix+A&rft.au=Hug%2C+Martin+J&rft.au=Staudacher%2C+Dawid+L&rft.date=2023-08-10&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2369&rft.eissn=1471-2369&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12882-023-03288-x&rft.externalDocID=A760390735 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2369&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2369&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2369&client=summon |